Cost-Effectiveness of Alternative Thresholds of the Fasting Plasma Glucose Test to Identify the Target Population for Type 2 Diabetes Prevention in Adults Aged ≥45 Years
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The study objective was to evaluate the cost-effectiveness of alternative fasting plasma glucose (FPG) thresholds to identify adults at high risk for type 2 diabetes for diabetes preventive intervention. RESEARCH DESIGN AND METHODS: We used a validated simulation model to examine the change in lifetime quality-adjusted life years (QALYs) and medical costs when the FPG threshold was progressively lowered in 5-mg/dL decrements from 120 to 90 mg/dL. The study sample includes nondiabetic adults aged ≥45 years in the United States using 2006–2010 data from the National Health and Nutrition Examination Survey. High-risk individuals were assumed to receive a lifestyle intervention, as that used in the Diabetes Prevention Program. We calculated cost per QALY by dividing the incremental cost by incremental QALY when lowering the threshold to the next consecutive level. Medical costs were assessed from a health care system perspective. We conducted univariate and probabilistic sensitivity analyses to assess the robustness of the results using different simulation scenarios and parameters. RESULTS: Progressively lowering the FPG threshold would monotonically increase QALYs, cost, and cost per QALY. Reducing (in 5-mg/dL decrements) the threshold from 120 to 90 mg/dL cost $30,100, $32,900, $42,300, $60,700, $81,800, and $115,800 per QALY gained, respectively. The costs per QALY gained were lower for all thresholds under a lower-cost and less-effective intervention scenario. CONCLUSIONS: Lowering the FPG threshold leads to a greater health benefit of diabetes prevention but reduces the cost-effectiveness. Using the conventional benchmark of $50,000 per QALY, a threshold of 105 mg/dL or higher would be cost effective. A lower threshold could be selected if the intervention cost could be lowered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Gestational Diabetes and the Incidence of Type 2 Diabetes
Kim, C., Newton, K. M., & Knopp, R. H. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1862 · Cited by 2,276
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s067 · Cited by 2,245
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Stevens, V. J., Obarzanek, E., Cook, N. R., Lee, I.-M., Appel, L. J., Smith West, D., Milas, N. C., Mattfeldt-Beman, M., Belden, L., Bragg, C., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00007 · Cited by 886
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Self-citationLevitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2147 · Cited by 668
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Translating the Diabetes Prevention Program into the Community
Ackermann, R. T., Finch, E. A., Brizendine, E., Zhou, H., & Marrero, D. G. (2008) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.06.035 · Cited by 622 · cited 1×
“Compared with the DPP intervention, PLAN4WARD costs about 75% less and was 60% as effective in reducing risk of diabetes (34).”
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Normal fasting plasma glucose levels and type 2 diabetes in young men
Tirosh, A., Shai, I., Tekes-Manova, D., Israeli, E., Pereg, D., Shochat, T., Kochba, I., & Rudich, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050080 · Cited by 508
Blood glucose and risk of cardiovascular disease in the Asia Pacific region.
Asia Pacific Cohort Studies Collaboration (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2836 · Cited by 302
Compliance with cardiovascular disease prevention strategies: A review of the research
Burke, L. E., Dunbar-Jacob, J. M., & Hill, M. N. (1997) · Annals of Behavioral Medicine · doi:10.1007/bf02892289 · Cited by 286
Heianza, Y., Hara, S., Arase, Y., Saito, K., Fujiwara, K., Tsuji, H., Kodama, S., Hsieh, S. D., Mori, Y., Shimano, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60472-8 · Cited by 260
Adapting the Diabetes Prevention Program Lifestyle Intervention for Delivery in the Community
Ackermann, R. T., & Marrero, D. G. (2007) · The Diabetes Educator · doi:10.1177/0145721706297743 · Cited by 220 · cited 1×
“PLAN4WARD is a community-based program designed to deliver at a lower cost the key elements of the lifestyle intervention used in the DPP study (33).”
The Relation of Fasting and 2-h Postchallenge Plasma Glucose Concentrations to Mortality
Sorkin, J. D., Muller, D. C., Fleg, J. L., & Andres, R. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2626 · Cited by 189
Screening for type 2 diabetes mellitus: a cost-effectiveness analysis
Hoerger, T. J., Harris, R., Hicks, K. A., Donahue, K., Sorensen, S., & Engelgau, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-9-200405040-00008 · Cited by 178
On behalf of, E. D. E. G., Forouhi, N. G., Balkau, B., Borch-Johnsen, K., Dekker, J., Glumer, C., Qiao, Q., Spijkerman, A., Stolk, R., Tabac, A., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0189-4 · Cited by 140
The utility of fasting glucose for detection of prediabetes
Cheng, C., Kushner, H., & Falkner, B. E. (2006) · Metabolism · doi:10.1016/j.metabol.2005.10.003 · Cited by 55 · cited 1×
“CONCLUSIONSdFPG tests have been increasingly used to identify individuals at high risk of developing type 2 diabetes and refer them for diabetes prevention interventions (38).”
Cited by
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationZhou, X., Siegel, K. R., Ng, B. P., Jawanda, S., Proia, K. K., Zhang, X., Albright, A. L., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dci20-0018 · Cited by 173
Self-citationZhang, X., Devlin, H. M., Smith, B., Imperatore, G., Thomas, W., Lobelo, F., Ali, M. K., Norris, K., Gruss, S., Bardenheier, B., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176436 · Cited by 110
Self-citationBardenheier, B. H., Wu, W.-C., Zullo, A. R., Gravenstein, S., & Gregg, E. W. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108726 · Cited by 16
Self-citation
Metadata
- Authors
- Zhuo, X., Zhang, P., Kahn, H. S., & Gregg, E. W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-11-13
- Volume
- 36
- Issue
- 12
- Pages
- 3992-3998
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2162890585
- Cited by
- 31
- References
- 20
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.